We presently don't have fully validated imaging or biomarker measures that can help us monitor the development or progression of Alzheimer's in living people. This study represents one step in the progress being made toward identifying clinically useful biological measures for AD.

146

It's really critical that we find ways to prevent, or at least delay the onset of, cognitive decline. Once the pathology is established in the brain, it's very difficult to treat. We need better ways to prevent the disease in the first place, which could make a huge difference for the future.

102